Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Opus Genetics ( (IRD) ) has shared an announcement.
On July 22, 2025, Opus Genetics entered into a funding and license agreement with Eyes on the Future and RDH12 Fund for Sight to develop gene therapies for inherited retinal degeneration associated with RDH12 gene mutations. The agreement provides up to $1.6 million in funding and includes a risk-sharing structure and performance-based milestones to accelerate the development of the OPGx-RDH12 program. This collaboration aims to file an Investigational New Drug application with the FDA by late 2025, marking a significant step forward in treating RDH12-associated Leber congenital amaurosis, a rare form of childhood blindness.
The most recent analyst rating on (IRD) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene and small molecule therapies for vision-threatening eye diseases. Their pipeline includes AAV-based gene therapies targeting inherited retinal diseases such as Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa, with their lead candidate OPGx-LCA5 currently in a Phase 1/2 trial.
Average Trading Volume: 1,083,591
Technical Sentiment Signal: Sell
Current Market Cap: $72.79M
For a thorough assessment of IRD stock, go to TipRanks’ Stock Analysis page.